Showing 1 - 9 results of 9 for search 'F Stephen Hodi', query time: 0.13s
Refine Results
-
1
-
2
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients by Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain
Published 2021-06-01
Article -
3
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma by Sebastian Bauer, James Larkin, F. Stephen Hodi, Frank Stephen, Frank Stephen, Ellen H. W. Kapiteijn, Gary K. Schwartz, Emilano Calvo, Padmaja Yerramilli-Rao, Sophie Piperno-Neumann, Richard D. Carvajal
Published 2023-06-01
Article -
4
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma by Krisztian Homicsko, Reinhard Dummer, Christoph Hoeller, Jedd D. Wolchok, F. Stephen Hodi, James Larkin, Paolo A. Ascierto, Victoria Atkinson, Caroline Robert, Michael A. Postow, Sandra Re, David Paulucci, Darin Dobler, Olivier Michielin
Published 2022-05-01
Article -
5
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors by Howard Streicher, Elad Sharon, Mariano Severgnini, Michael Manos, Anita Giobbie-Hurder, F Stephen Hodi, Andrew S Brohl, Philippe L Bedard, Kevin Tyan, Scott Rodig, Osama E Rahma, Daniel J Renouf, Emma Hathaway, Rachel Cunningham
Published 2022-03-01
Article -
6
578 Anti-PD-1 therapy alters the generation and durability of de novo responses to vaccination in humans by Michael Manos, Arlene Sharpe, F Stephen Hodi, Joanna Baginska, Elizabeth I Buchbinder, Marta Holovatska, Kelly P Burke, Taras M Chicz, Julia Huezo, Duck Kyun Yoo, Fnu Keerti, Caihong Bi, Ryan McNamara, Duane Wesemann
Published 2023-11-01Article -
7
45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma... by Lisa H Butterfield, Howard Streicher, Patrick Hwu, Walter J Storkus, Ahmad A Tarhini, John M Kirkwood, F Stephen Hodi, Dung-Tsa Chen, Sandra J Lee, Issam El Naqa, William A LaFramboise, Arivarasan D Karunamurthy, Timothy I Shaw, Alyssa Obermayer
Published 2023-11-01Article -
8
700 Increasing MHC-I expression to potentiate immune checkpoint blockade therapy by Peng Jiang, Xia Bu, Michael Manos, Ana Lako, Scott Rodig, Yingtian Xie, Shengqing Gu, Henry Long, Paloma Cejas, Gordon Freeman, Wubing Zhang, Xiaoqing Wang, Nicole Traugh, Ziyi Li, Clifford Meyer, Blair Stewig, Alba Font-Tello, Klothilda Lim, Jake Conway, Alok Tewari, Zexian Zeng, Avinash Das Sahu, Collin Tokheim, Jason Weirather, Jingxin Fu, Benjamin Kroger, Jin Hua Liang, Benjamin Gewurz, F. Stephen Hodi, Myles Brown, X Shirley Liu
Published 2021-11-01Article -
9
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
Published 2023-03-01
Article